HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CUTIA-B

1.600

-0.035-2.14%

Volume:117.40K

Turnover:186.88K

Market Cap:596.80M

PE:-1.55

High:1.635

Open:1.635

Low:1.570

Close:1.635

52wk High:11.200

52wk Low:1.570

Shares:373.00M

HK Float Shares:373.00M

Volume Ratio:1.69

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.030

ROE:-38.30%

ROA:-14.05%

PB:0.72

PE(LYR):-1.55

PS:1.54

Loading ...

Overview Company News Filings

CUTIA-B Keeps Share Count Flat in April; 230,110 Options and 2.06 Million Share Awards Forfeited

Bulletin Express

CUTIA-B (02487) Receives NMPA Approval for CU-30101, a Topical Lidocaine-Tetracaine Cream

Cutia-B obtains NMPA marketing nod for CU-30101 lidocaine-tetracaine topical anesthetic

Bulletin Express

Cutia Therapeutics says NMPA approves CU-30101 topical lidocaine-tetracaine cream

Cutia Therapeutics - Cu-30101 Obtains Drug Marketing Authorization by Nmpa in China

THOMSON REUTERS

Fidelity China Fund Boosts Stake in Cutia-B with 30,600 Share Purchase

Cutia Therapeutics Updates Cayman Registrar Name to Ascentium (Cayman) Limited

Bulletin Express

Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩

Bulletin Express

Cutia Posts RMB336.20 Million Revenue; ESG Drive Cuts Carbon Intensity 16.67 %

Bulletin Express

CUTIA-B schedules 26 Jun 2026 AGM to approve board renewals, 10% buyback and 20% issuance mandates

Bulletin Express

Cutia Therapeutics announces annual general meeting

Cutia Therapeutics publishes 2025 annual report

CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin

Cutia Therapeutics completes China Phase III trial of CU-20101 for glabellar lines

Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product

MT Newswires Live

BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101

CUTIA-B Completes Phase III Trial in China for Botulinum Toxin Type A Injection Targeting Glabellar Lines

Cutia Therapeutics - Completion of Phase Iii Clinical Trial of Cu-20101

THOMSON REUTERS

Cutia Therapeutics Reports Stable Share Capital in March; Confirms Public-Float Compliance

Bulletin Express

Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/02487/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02487","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02487\",,,,,undefined,":{"symbol":"02487","market":"HK","secType":"STK","nameCN":"CUTIA-B","latestPrice":1.6,"timestamp":1789026937472,"preClose":1.635,"halted":0,"volume":117400,"delay":0,"changeRate":-0.021406727828746128,"floatShares":373000000,"shares":373000000,"eps":-1.03,"marketStatus":"Not Yet Opened","change":-0.035,"latestTime":"09-10 15:55:37","open":1.635,"high":1.635,"low":1.57,"amount":186881,"amplitude":0.039755,"askPrice":1.73,"askSize":5000,"bidPrice":1.6,"bidSize":51800,"shortable":0,"etf":0,"ttmEps":-0.868,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1686499200000,"exchange":"SEHK","adjPreClose":1.635,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.689695,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02487\",,,,,undefined,":{"symbol":"02487","floatShares":373000000,"roa":"-14.05%","roe":"-38.30%","lyrEps":-1.03,"volumeRatio":1.689695,"shares":373000000,"dividePrice":0,"high":1.635,"amplitude":0.039755,"preClose":1.635,"low":1.57,"week52Low":1.57,"pbRate":"0.72","psRate":"1.54","week52High":11.2,"institutionHeld":0,"latestPrice":1.6,"committee":0.823944,"eps":-1.03,"divideRate":0,"volume":117400,"delay":0,"ttmEps":-0.868,"open":1.635,"prevYearClose":4.54,"prevWeekClose":1.745,"prevMonthClose":1.91,"prevQuarterClose":2.83,"fiveDayClose":1.75,"twentyDayClose":2.32,"sixtyDayClose":3.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02487\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02487","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"market":"HK","date":"2026-03-24","symbol":"02487","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774281600000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-28","symbol":"02487","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null},{"date":"2025-03-24","symbol":"02487","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post-Mkt","dateTimestamp":1742745600000,"actualEps":null},{"market":"HK","date":"2024-08-29","symbol":"02487","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1724860800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02487\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02487\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1774972800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02487\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02487","date":"2026-09-09","current":-1.843318,"percent":0.778473,"low":-15.485925,"twenty":-6.120704,"median":-3.375404,"eighty":-1.45701,"high":-0.826569,"avg":-4.067857,"sd":2.786676,"marketCap":594107132},"quantilePoints":[{"date":"2023-06-16","current":-15.411162,"twenty":-14.413676,"median":-12.389874,"eighty":-12.075055,"marketCap":9394355968},{"date":"2023-06-23","current":-12.436662,"twenty":-14.898766,"median":-13.544522,"eighty":-12.376412,"marketCap":7539806732},{"date":"2023-06-30","current":-12.398371,"twenty":-14.32145,"median":-12.394122,"eighty":-11.447458,"marketCap":7448599392},{"date":"2023-07-07","current":-11.154992,"twenty":-13.792435,"median":-12.336647,"eighty":-11.411148,"marketCap":6688538230},{"date":"2023-07-14","current":-10.800615,"twenty":-12.879806,"median":-11.67313,"eighty":-11.073156,"marketCap":6566928444},{"date":"2023-07-21","current":-9.796084,"twenty":-12.413687,"median":-11.417592,"eighty":-10.790615,"marketCap":5928477067},{"date":"2023-07-28","current":-10.460353,"twenty":-12.393273,"median":-11.232297,"eighty":-10.42688,"marketCap":6323708872},{"date":"2023-08-04","current":-10.844647,"twenty":-12.36968,"median":-11.144468,"eighty":-10.471016,"marketCap":6566928444},{"date":"2023-08-11","current":-11.613111,"twenty":-12.376412,"median":-11.154992,"eighty":-10.495819,"marketCap":6992562695},{"date":"2023-08-18","current":-11.061159,"twenty":-12.34839,"median":-11.14973,"eighty":-10.533878,"marketCap":6612532113},{"date":"2023-08-25","current":-12.606042,"twenty":-12.421346,"median":-11.281516,"eighty":-10.611978,"marketCap":7539806732},{"date":"2023-09-01","current":-3.762061,"twenty":-12.421346,"median":-11.154992,"eighty":-10.467461,"marketCap":7904636090},{"date":"2023-09-08","current":-3.045502,"twenty":-12.394972,"median":-11.061159,"eighty":-10.227752,"marketCap":6323708872},{"date":"2023-09-15","current":-3.276331,"twenty":-12.381613,"median":-10.935179,"eighty":-6.512762,"marketCap":6855751685},{"date":"2023-09-22","current":-3.006155,"twenty":-12.36402,"median":-10.844647,"eighty":-3.792803,"marketCap":6262903979},{"date":"2023-09-29","current":-2.913601,"twenty":-12.34839,"median":-10.788114,"eighty":-3.305013,"marketCap":6080489300},{"date":"2023-10-06","current":-3.060747,"twenty":-12.287596,"median":-10.741943,"eighty":-3.213384,"marketCap":6384513765},{"date":"2023-10-13","current":-3.036132,"twenty":-12.066426,"median":-10.551151,"eighty":-3.148051,"marketCap":6323708872},{"date":"2023-10-20","current":-3.106604,"twenty":-11.932534,"median":-10.469238,"eighty":-3.120451,"marketCap":6460519881},{"date":"2023-10-27","current":-2.925118,"twenty":-11.796455,"median":-10.343076,"eighty":-3.068613,"marketCap":6080489300},{"date":"2023-11-03","current":-2.990305,"twenty":-11.691357,"median":-10.218458,"eighty":-3.045502,"marketCap":6232501532},{"date":"2023-11-10","current":-3.268138,"twenty":-11.654904,"median":-9.796084,"eighty":-3.060747,"marketCap":6810148016},{"date":"2023-11-17","current":-3.108791,"twenty":-11.613111,"median":-4.217909,"eighty":-3.060747,"marketCap":6536525997},{"date":"2023-11-24","current":-2.853944,"twenty":-11.467369,"median":-3.800488,"eighty":-3.019641,"marketCap":6050086853},{"date":"2023-12-01","current":-2.756466,"twenty":-11.417592,"median":-3.514265,"eighty":-2.990305,"marketCap":5867672174},{"date":"2023-12-08","current":-2.351787,"twenty":-11.401481,"median":-3.313885,"eighty":-2.93822,"marketCap":4986001226},{"date":"2023-12-15","current":-1.83926,"twenty":-11.309603,"median":-3.276331,"eighty":-2.913601,"marketCap":3921915598},{"date":"2023-12-22","current":-1.398202,"twenty":-11.281516,"median":-3.266894,"eighty":-2.872719,"marketCap":2979439757},{"date":"2023-12-29","current":-1.558248,"twenty":-11.205602,"median":-3.218707,"eighty":-2.860632,"marketCap":3338188625},{"date":"2024-01-05","current":-1.057644,"twenty":-11.154992,"median":-3.21182,"eighty":-2.802771,"marketCap":2249781041},{"date":"2024-01-12","current":-0.999942,"twenty":-11.150782,"median":-3.160184,"eighty":-2.759084,"marketCap":2128171255},{"date":"2024-01-19","current":-0.956974,"twenty":-11.111144,"median":-3.130992,"eighty":-2.490877,"marketCap":2033923670},{"date":"2024-01-26","current":-1.01241,"twenty":-11.026152,"median":-3.120712,"eighty":-2.309623,"marketCap":2143372478},{"date":"2024-02-02","current":-0.936815,"twenty":-10.964346,"median":-3.106604,"eighty":-1.836456,"marketCap":1980801062},{"date":"2024-02-09","current":-0.896369,"twenty":-10.938224,"median":-3.073227,"eighty":-1.544488,"marketCap":1904616406},{"date":"2024-02-16","current":-0.959266,"twenty":-10.919956,"median":-3.067843,"eighty":-1.412953,"marketCap":2038701401},{"date":"2024-02-23","current":-0.899483,"twenty":-10.863612,"median":-3.062215,"eighty":-1.31118,"marketCap":1901569020},{"date":"2024-03-01","current":-1.152465,"twenty":-10.844647,"median":-3.040182,"eighty":-1.17923,"marketCap":2437909000},{"date":"2024-03-08","current":-0.971959,"twenty":-10.843385,"median":-3.012898,"eighty":-1.152465,"marketCap":2056985718},{"date":"2024-03-15","current":-1.145767,"twenty":-10.800615,"median":-3.003359,"eighty":-1.102403,"marketCap":2422672068},{"date":"2024-03-22","current":-1.210287,"twenty":-10.775614,"median":-2.971683,"eighty":-1.108733,"marketCap":2556757063},{"date":"2024-03-28","current":-1.130651,"twenty":-10.768565,"median":-2.94471,"eighty":-1.126268,"marketCap":2404387751},{"date":"2024-04-05","current":-1.018114,"twenty":-10.746915,"median":-2.925118,"eighty":-1.078437,"marketCap":2163644237},{"date":"2024-04-12","current":-1.011803,"twenty":-10.711537,"median":-2.916466,"eighty":-1.052694,"marketCap":2151454692},{"date":"2024-04-19","current":-0.965334,"twenty":-10.642392,"median":-2.906537,"eighty":-1.046989,"marketCap":2050890946},{"date":"2024-04-26","current":-1.03546,"twenty":-10.539635,"median":-2.868164,"eighty":-1.036496,"marketCap":2197165486},{"date":"2024-05-03","current":-1.095099,"twenty":-10.513514,"median":-2.860037,"eighty":-1.038246,"marketCap":2322108322},{"date":"2024-05-10","current":-1.015083,"twenty":-10.47457,"median":-2.807837,"eighty":-1.032578,"marketCap":2157549465},{"date":"2024-05-17","current":-1.060526,"twenty":-10.460353,"median":-2.785798,"eighty":-1.029219,"marketCap":2239828893},{"date":"2024-05-24","current":-1.149726,"twenty":-10.37667,"median":-2.759739,"eighty":-1.030854,"marketCap":2422672068},{"date":"2024-05-31","current":-1.040202,"twenty":-10.309482,"median":-2.716272,"eighty":-1.030854,"marketCap":2194118100},{"date":"2024-06-07","current":-0.954703,"twenty":-10.241692,"median":-2.483148,"eighty":-1.020882,"marketCap":2011274925},{"date":"2024-06-14","current":-0.88753,"twenty":-10.223105,"median":-2.348826,"eighty":-1.015017,"marketCap":1868047771},{"date":"2024-06-21","current":-0.879235,"twenty":-9.893357,"median":-2.097181,"eighty":-1.011704,"marketCap":1846716067},{"date":"2024-06-28","current":-0.930402,"twenty":-9.799284,"median":-1.836923,"eighty":-1.004715,"marketCap":1953374586},{"date":"2024-07-05","current":-0.911731,"twenty":-9.796084,"median":-1.670031,"eighty":-0.989934,"marketCap":1913758565},{"date":"2024-07-12","current":-0.998824,"twenty":-6.512762,"median":-1.535315,"eighty":-0.975822,"marketCap":2099649126},{"date":"2024-07-19","current":-1.078316,"twenty":-4.260297,"median":-1.440488,"eighty":-0.983109,"marketCap":2266795296},{"date":"2024-07-26","current":-1.109957,"twenty":-4.076914,"median":-1.398202,"eighty":-0.988979,"marketCap":2341976752},{"date":"2024-08-02","current":-1.019736,"twenty":-3.896516,"median":-1.341466,"eighty":-0.989934,"marketCap":2150360472},{"date":"2024-08-09","current":-1.088923,"twenty":-3.792803,"median":-1.273961,"eighty":-0.992426,"marketCap":2311561470},{"date":"2024-08-16","current":-1.21024,"twenty":-3.761985,"median":-1.221942,"eighty":-0.996911,"marketCap":2570091371},{"date":"2024-08-23","current":-1.4747,"twenty":-3.613333,"median":-1.260835,"eighty":-0.999495,"marketCap":3144940210},{"date":"2024-08-30","current":-6.768747,"twenty":-3.613333,"median":-1.282548,"eighty":-1.003043,"marketCap":3899239216},{"date":"2024-09-06","current":-6.86048,"twenty":-4.076914,"median":-1.344748,"eighty":-1.005589,"marketCap":3953986725},{"date":"2024-09-13","current":-7.629828,"twenty":-6.773268,"median":-1.399159,"eighty":-1.006459,"marketCap":4385883736},{"date":"2024-09-20","current":-7.679018,"twenty":-6.86048,"median":-1.408171,"eighty":-1.008176,"marketCap":4440631245},{"date":"2024-09-27","current":-8.467696,"twenty":-7.210357,"median":-1.4747,"eighty":-1.010386,"marketCap":4926157965},{"date":"2024-10-04","current":-8.045497,"twenty":-7.438254,"median":-1.528968,"eighty":-1.010794,"marketCap":4659279943},{"date":"2024-10-10","current":-6.916807,"twenty":-7.445917,"median":-1.535454,"eighty":-1.011308,"marketCap":3979699659},{"date":"2024-10-18","current":-6.535297,"twenty":-7.4076,"median":-1.599022,"eighty":-1.011803,"marketCap":3740585295},{"date":"2024-10-25","current":-6.87674,"twenty":-7.395,"median":-1.716627,"eighty":-1.011971,"marketCap":3935766258},{"date":"2024-11-01","current":-6.487355,"twenty":-7.390607,"median":-1.836923,"eighty":-1.01241,"marketCap":3715412316},{"date":"2024-11-08","current":-5.268552,"twenty":-7.067714,"median":-2.097181,"eighty":-1.012524,"marketCap":2994521565},{"date":"2024-11-15","current":-4.934518,"twenty":-6.939983,"median":-2.348826,"eighty":-1.014752,"marketCap":2783467441},{"date":"2024-11-22","current":-4.525008,"twenty":-6.921031,"median":-2.487824,"eighty":-1.015083,"marketCap":2551002028},{"date":"2024-11-29","current":-4.212716,"twenty":-6.916807,"median":-2.719501,"eighty":-1.015704,"marketCap":2373594213},{"date":"2024-12-06","current":-4.301808,"twenty":-6.905598,"median":-2.763011,"eighty":-1.018114,"marketCap":2418082775},{"date":"2024-12-13","current":-4.02776,"twenty":-6.88455,"median":-2.792596,"eighty":-1.019736,"marketCap":2261974665},{"date":"2024-12-20","current":-3.895979,"twenty":-6.880216,"median":-2.853944,"eighty":-1.020882,"marketCap":2175955910},{"date":"2024-12-27","current":-3.693493,"twenty":-6.879252,"median":-2.860037,"eighty":-1.021555,"marketCap":2061264237},{"date":"2025-01-03","current":-3.393321,"twenty":-6.877861,"median":-2.868164,"eighty":-1.023476,"marketCap":1895598486},{"date":"2025-01-10","current":-2.994045,"twenty":-6.870236,"median":-2.906537,"eighty":-1.026058,"marketCap":1666215140},{"date":"2025-01-17","current":-2.591221,"twenty":-6.86048,"median":-2.868164,"eighty":-1.027008,"marketCap":1443203553},{"date":"2025-01-24","current":-2.296545,"twenty":-6.833199,"median":-2.860899,"eighty":-1.028243,"marketCap":1287095443},{"date":"2025-01-28","current":-2.466671,"twenty":-6.805918,"median":-2.857066,"eighty":-1.028894,"marketCap":1389043597},{"date":"2025-02-07","current":-2.798033,"twenty":-6.785996,"median":-2.820002,"eighty":-1.030527,"marketCap":1567452866},{"date":"2025-02-14","current":-3.403301,"twenty":-6.780924,"median":-2.832166,"eighty":-1.031664,"marketCap":1901970246},{"date":"2025-02-21","current":-2.965189,"twenty":-6.771007,"median":-2.858982,"eighty":-1.034711,"marketCap":1666215140},{"date":"2025-02-28","current":-3.128579,"twenty":-6.737748,"median":-2.857066,"eighty":-1.035452,"marketCap":1752233895},{"date":"2025-03-07","current":-3.795937,"twenty":-6.685693,"median":-2.863309,"eighty":-1.035834,"marketCap":2134539472},{"date":"2025-03-14","current":-3.17157,"twenty":-6.632156,"median":-2.878989,"eighty":-1.03679,"marketCap":1784092693},{"date":"2025-03-21","current":-3.342788,"twenty":-6.586773,"median":-2.907899,"eighty":-1.03784,"marketCap":1879669087},{"date":"2025-03-28","current":-4.261325,"twenty":-6.543854,"median":-2.91933,"eighty":-1.038839,"marketCap":1978431362},{"date":"2025-04-03","current":-3.930581,"twenty":-6.51804,"median":-2.925118,"eighty":-1.039278,"marketCap":1825509131},{"date":"2025-04-11","current":-3.073189,"twenty":-6.495027,"median":-2.922242,"eighty":-1.03967,"marketCap":1414530635},{"date":"2025-04-17","current":-3.165897,"twenty":-6.47136,"median":-2.94471,"eighty":-1.039975,"marketCap":1459132952},{"date":"2025-04-25","current":-3.918674,"twenty":-6.44197,"median":-2.955046,"eighty":-1.041501,"marketCap":1809579732},{"date":"2025-05-02","current":-4.151319,"twenty":-6.420376,"median":-2.965975,"eighty":-1.046698,"marketCap":1921085525},{"date":"2025-05-09","current":-4.238599,"twenty":-6.416374,"median":-2.989735,"eighty":-1.04728,"marketCap":1975245482},{"date":"2025-05-16","current":-4.366995,"twenty":-6.405055,"median":-3.003359,"eighty":-1.048429,"marketCap":2051706597},{"date":"2025-05-23","current":-5.848115,"twenty":-6.313401,"median":-3.007935,"eighty":-1.050731,"marketCap":2755786035},{"date":"2025-05-30","current":-6.515833,"twenty":-6.416374,"median":-3.036132,"eighty":-1.051354,"marketCap":3083931656},{"date":"2025-06-06","current":-6.996095,"twenty":-6.508395,"median":-3.039313,"eighty":-1.052,"marketCap":3319686762},{"date":"2025-06-13","current":-8.228236,"twenty":-6.545559,"median":-3.060747,"eighty":-1.052348,"marketCap":3905888647},{"date":"2025-06-20","current":-6.374949,"twenty":-6.632156,"median":-3.067399,"eighty":-1.052744,"marketCap":3020214059},{"date":"2025-06-27","current":-6.3035,"twenty":-6.639184,"median":-3.073189,"eighty":-1.053079,"marketCap":2994727021},{"date":"2025-07-04","current":-5.954515,"twenty":-6.641618,"median":-3.086246,"eighty":-1.054062,"marketCap":2829061271},{"date":"2025-07-11","current":-5.819562,"twenty":-6.627625,"median":-3.114534,"eighty":-1.055579,"marketCap":2762157795},{"date":"2025-07-18","current":-6.720769,"twenty":-6.641618,"median":-3.123457,"eighty":-1.057059,"marketCap":3187401188},{"date":"2025-07-25","current":-6.141724,"twenty":-6.627625,"median":-3.129786,"eighty":-1.059373,"marketCap":2923374942},{"date":"2025-08-01","current":-5.729361,"twenty":-6.595465,"median":-3.139962,"eighty":-1.061686,"marketCap":2710245321},{"date":"2025-08-08","current":-5.735189,"twenty":-6.557071,"median":-3.15919,"eighty":-1.06292,"marketCap":2719788439},{"date":"2025-08-15","current":-6.274508,"twenty":-6.540468,"median":-3.165897,"eighty":-1.063408,"marketCap":2971090528},{"date":"2025-08-22","current":-6.442504,"twenty":-6.540468,"median":-3.175987,"eighty":-1.065225,"marketCap":3041073389},{"date":"2025-08-29","current":-7.115719,"twenty":-6.557071,"median":-3.21131,"eighty":-1.067861,"marketCap":3674100172},{"date":"2025-09-05","current":-7.091352,"twenty":-6.584214,"median":-3.213297,"eighty":-1.074535,"marketCap":3657890365},{"date":"2025-09-12","current":-6.910072,"twenty":-6.659199,"median":-3.2277,"eighty":-1.082356,"marketCap":3570797737},{"date":"2025-09-19","current":-6.382019,"twenty":-6.693078,"median":-3.259314,"eighty":-1.087373,"marketCap":3295585034},{"date":"2025-09-26","current":-5.904859,"twenty":-6.659199,"median":-3.275781,"eighty":-1.091631,"marketCap":3041274561},{"date":"2025-10-03","current":-6.01226,"twenty":-6.644052,"median":-3.290255,"eighty":-1.094101,"marketCap":3103981253},{"date":"2025-10-10","current":-5.838578,"twenty":-6.633708,"median":-3.310057,"eighty":-1.095198,"marketCap":3009921215},{"date":"2025-10-17","current":-5.559086,"twenty":-6.615916,"median":-3.325304,"eighty":-1.096113,"marketCap":2863605600},{"date":"2025-10-24","current":-5.333971,"twenty":-6.590347,"median":-3.359906,"eighty":-1.098444,"marketCap":2748643331},{"date":"2025-10-31","current":-5.083015,"twenty":-6.578081,"median":-3.393321,"eighty":-1.099475,"marketCap":2623229947},{"date":"2025-11-07","current":-4.181079,"twenty":-6.543931,"median":-3.413605,"eighty":-1.102403,"marketCap":2156413463},{"date":"2025-11-14","current":-4.822607,"twenty":-6.543065,"median":-3.495515,"eighty":-1.108733,"marketCap":2494332858},{"date":"2025-11-21","current":-4.392956,"twenty":-6.538737,"median":-3.605298,"eighty":-1.109957,"marketCap":2271051731},{"date":"2025-11-28","current":-4.594159,"twenty":-6.537428,"median":-3.670872,"eighty":-1.109957,"marketCap":2383695897},{"date":"2025-12-05","current":-4.264675,"twenty":-6.535297,"median":-3.715228,"eighty":-1.111553,"marketCap":2216546489},{"date":"2025-12-12","current":-4.110256,"twenty":-6.53384,"median":-3.762061,"eighty":-1.113705,"marketCap":2140239151},{"date":"2025-12-19","current":-3.613255,"twenty":-6.530763,"median":-3.749448,"eighty":-1.113705,"marketCap":1885881357},{"date":"2025-12-24","current":-3.608975,"twenty":-6.526072,"median":-3.693493,"eighty":-1.114207,"marketCap":1889515040},{"date":"2026-01-02","current":-3.173126,"twenty":-6.5201,"median":-3.677848,"eighty":-1.115526,"marketCap":1667860391},{"date":"2026-01-09","current":-3.585899,"twenty":-6.512114,"median":-3.657564,"eighty":-1.121582,"marketCap":1889515040},{"date":"2026-01-16","current":-3.285591,"twenty":-6.502385,"median":-3.621768,"eighty":-1.129331,"marketCap":1736900364},{"date":"2026-01-23","current":-3.268106,"twenty":-6.492637,"median":-3.611115,"eighty":-1.133662,"marketCap":1725999315},{"date":"2026-01-30","current":-3.301176,"twenty":-6.480864,"median":-3.592259,"eighty":-1.140204,"marketCap":1751435095},{"date":"2026-02-06","current":-3.620741,"twenty":-6.465168,"median":-3.583052,"eighty":-1.144251,"marketCap":1925851868},{"date":"2026-02-13","current":-3.498174,"twenty":-6.452683,"median":-3.572107,"eighty":-1.147341,"marketCap":1871346626},{"date":"2026-02-20","current":-3.469208,"twenty":-6.44914,"median":-3.529701,"eighty":-1.148914,"marketCap":1853178212},{"date":"2026-02-27","current":-3.108602,"twenty":-6.443477,"median":-3.500418,"eighty":-1.149721,"marketCap":1678761439},{"date":"2026-03-06","current":-3.188132,"twenty":-6.431634,"median":-3.482285,"eighty":-1.150014,"marketCap":1707830901},{"date":"2026-03-13","current":-3.37608,"twenty":-6.424297,"median":-3.46792,"eighty":-1.151989,"marketCap":1816841385},{"date":"2026-03-20","current":-3.050022,"twenty":-6.420929,"median":-3.449202,"eighty":-1.157177,"marketCap":1635157246},{"date":"2026-03-27","current":-4.490263,"twenty":-6.416374,"median":-3.449778,"eighty":-1.164557,"marketCap":1729632998},{"date":"2026-04-02","current":-4.34674,"twenty":-6.411798,"median":-3.46792,"eighty":-1.170777,"marketCap":1682395122},{"date":"2026-04-10","current":-4.294839,"twenty":-6.408569,"median":-3.475043,"eighty":-1.174833,"marketCap":1675127756},{"date":"2026-04-17","current":-4.42341,"twenty":-6.404645,"median":-3.496844,"eighty":-1.178732,"marketCap":1725999315},{"date":"2026-04-24","current":-4.413848,"twenty":-6.398384,"median":-3.514265,"eighty":-1.179711,"marketCap":1722365632},{"date":"2026-04-30","current":-4.282382,"twenty":-6.382019,"median":-3.572107,"eighty":-1.181633,"marketCap":1671494074},{"date":"2026-05-08","current":-4.249016,"twenty":-6.374949,"median":-3.589079,"eighty":-1.198373,"marketCap":1664226708},{"date":"2026-05-15","current":-4.052809,"twenty":-6.34837,"median":-3.608975,"eighty":-1.21024,"marketCap":1591553053},{"date":"2026-05-22","current":-3.858061,"twenty":-6.318006,"median":-3.618969,"eighty":-1.210287,"marketCap":1511612032},{"date":"2026-05-29","current":-3.317895,"twenty":-6.306401,"median":-3.615796,"eighty":-1.214673,"marketCap":1304492114},{"date":"2026-06-05","current":-3.303858,"twenty":-6.293606,"median":-3.592369,"eighty":-1.225646,"marketCap":1300858431},{"date":"2026-06-12","current":-2.973638,"twenty":-6.288695,"median":-3.583052,"eighty":-1.242193,"marketCap":1170045851},{"date":"2026-06-18","current":-2.948095,"twenty":-6.279939,"median":-3.550904,"eighty":-1.254786,"marketCap":1162778486},{"date":"2026-06-26","current":-2.499662,"twenty":-6.270524,"median":-3.502662,"eighty":-1.268711,"marketCap":981094347},{"date":"2026-07-03","current":-2.534798,"twenty":-6.254076,"median":-3.495515,"eighty":-1.27574,"marketCap":995629078},{"date":"2026-07-10","current":-2.454551,"twenty":-6.23066,"median":-3.472125,"eighty":-1.281721,"marketCap":962925934},{"date":"2026-07-17","current":-2.242795,"twenty":-6.221134,"median":-3.450354,"eighty":-1.296485,"marketCap":882984913},{"date":"2026-07-24","current":-2.223836,"twenty":-6.201146,"median":-3.436238,"eighty":-1.324607,"marketCap":875717547},{"date":"2026-07-31","current":-2.155149,"twenty":-6.18189,"median":-3.419231,"eighty":-1.350149,"marketCap":850281768},{"date":"2026-08-07","current":-2.325624,"twenty":-6.175555,"median":-3.403301,"eighty":-1.377042,"marketCap":919321740},{"date":"2026-08-14","current":-2.047266,"twenty":-6.16769,"median":-3.397557,"eighty":-1.398585,"marketCap":810311257},{"date":"2026-08-21","current":-1.786263,"twenty":-6.139816,"median":-3.393321,"eighty":-1.400771,"marketCap":708568140},{"date":"2026-08-28","current":-1.790437,"twenty":-6.131021,"median":-3.380823,"eighty":-1.405303,"marketCap":710384981},{"date":"2026-09-04","current":-1.932601,"twenty":-6.124956,"median":-3.375969,"eighty":-1.423967,"marketCap":634077643},{"date":"2026-09-09","current":-1.807882,"twenty":-6.120704,"median":-3.375404,"eighty":-1.45701,"marketCap":594107132}],"updateTime":1789058033579},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02487\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176788793","title":"CUTIA-B Keeps Share Count Flat in April; 230,110 Options and 2.06 Million Share Awards Forfeited","url":"https://stock-news.laohu8.com/highlight/detail?id=1176788793","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176788793?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:03","pubTimestamp":1778159000,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (stock short name: CUTIA-B) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 30 April 2026. The filing shows no changes to authorised capital or...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125162194","title":"CUTIA-B (02487) Receives NMPA Approval for CU-30101, a Topical Lidocaine-Tetracaine Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=1125162194","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125162194?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:48","pubTimestamp":1778107722,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) announced that its CU-30101, a topical lidocaine-tetracaine cream, has obtained drug marketing authorization from the National Medical Products Administration (NMPA) of China....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150742320","title":"Cutia-B obtains NMPA marketing nod for CU-30101 lidocaine-tetracaine topical anesthetic","url":"https://stock-news.laohu8.com/highlight/detail?id=1150742320","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150742320?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:42","pubTimestamp":1778107373,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (Cutia-B) has received drug marketing authorization from China’s National Medical Products Administration (NMPA) for CU-30101, a localized lidocaine and tetracaine compound cream...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633651611","title":"Cutia Therapeutics says NMPA approves CU-30101 topical lidocaine-tetracaine cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2633651611","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633651611?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:40","pubTimestamp":1778107219,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics secured China NMPA marketing authorization for CU-30101, a topical lidocaine-tetracaine anesthetic cream.Clearance was supported by a China Phase III trial showing comparable pain relief to control drug Pliaglis, with a favorable safety profile.CU-30101 becomes Cutia third NMPA-approved product, expanding its footprint in topical anesthesia and broader dermatology commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL6q4l5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633516599","title":"Cutia Therapeutics - Cu-30101 Obtains Drug Marketing Authorization by Nmpa in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2633516599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633516599?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:37","pubTimestamp":1778107066,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J1NU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190884779","title":"Fidelity China Fund Boosts Stake in Cutia-B with 30,600 Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1190884779","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190884779?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:32","pubTimestamp":1777375953,"startTime":"0","endTime":"0","summary":"On April 23, Fidelity China Special Situations PLC increased its holding in Cutia-B (02487) by 30,600 shares. The transaction was executed at a price of HK$4.6041 per share, involving a total...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153511949","title":"Cutia Therapeutics Updates Cayman Registrar Name to Ascentium (Cayman) Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=1153511949","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153511949?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:03","pubTimestamp":1777295031,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics announced that, effective 17 April 2026, the name of its principal share registrar, transfer office and registered office in the Cayman Islands has been changed from Harneys...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104183992","title":"Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1104183992","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104183992?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:54","pubTimestamp":1777020895,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics于2025年度实现收入人民币3.362亿（上年同期为2.796亿），同比增长20.2%。公司重点推出的两款皮肤科核心产品——CU-40102（外用非那雄胺喷雾）与CU-10201（外用4%米诺环素气泡沫剂）于2025年10月底在中国获批并上市，为整体收入带来主要增量。同时，头皮护理和皮肤护理等既有业务保持稳定需求，进一步支撑销售。...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cutia Therapeutics 2025年度简讯：收入同比增20.2%至3.362亿人民币，核心皮肤科产品商业化显著提升业绩","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171173533","title":"Cutia Posts RMB336.20 Million Revenue; ESG Drive Cuts Carbon Intensity 16.67 %","url":"https://stock-news.laohu8.com/highlight/detail?id=1171173533","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171173533?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:45","pubTimestamp":1777020339,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B) released its 2025 Environmental, Social & Governance Report, highlighting a year of commercial milestones and measurable sustainability gains. Financial and Commercial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198997593","title":"CUTIA-B schedules 26 Jun 2026 AGM to approve board renewals, 10% buyback and 20% issuance mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1198997593","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198997593?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:45","pubTimestamp":1777020303,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B) has issued a circular convening its Annual General Meeting for 10:00 a.m. on 26 June 2026 at its Shanghai headquarters. Key resolutions: 1. Board composition   • Five...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629857819","title":"Cutia Therapeutics announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629857819","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629857819?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:39","pubTimestamp":1777019977,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics will hold its annual general meeting in Shanghai on June 26, 2026.Shareholders will receive audited consolidated financial statements and directors’ and auditors’ reports for fiscal 2025.Votes will be held on re-election of board members, including non-executive and independent non-executive directors.Resolution will seek authority for directors to set directors’ remuneration.Proposals include re-appointing Ernst & Young as auditor, share repurchase mandate up to 10%, share issuance mandate up to 20%, and an extension of issuance capacity linked to any shares repurchased.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the Issu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL7w9HXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629481613","title":"Cutia Therapeutics publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629481613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629481613?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:31","pubTimestamp":1777019504,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics released its 2025 annual report, highlighting rapid ramp-up in commercialization of key dermatology products.Topical finasteride spray CU-40102 secured China marketing clearance in June 2025, gained Hong Kong clearance in August 2025.Topical minocycline foam CU-10201, cleared in China in November 2024, began broader commercial rollout in late October 2025 alongside CU-40102.Localized adipose candidate CU-20401 posted positive Phase II results in China, setting up move toward Phase III.Management outlook flagged planned expansion of CU-10201, CU-40102 sales channels in 2026, with CU-30101 topical anesthetic positioned for potential China launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL6B9nF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139617375","title":"CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin","url":"https://stock-news.laohu8.com/highlight/detail?id=1139617375","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139617375?lang=en_us&edition=fundamental","pubTime":"2026-04-13 13:42","pubTimestamp":1776058937,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) rose more than 3% during trading. At the time of writing, the stock was up 3.25%, trading at HK$4.76, with a turnover of HK$409,900. The company announced the completion of its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","VXUS","III","BK4588","BK4134","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627886324","title":"Cutia Therapeutics completes China Phase III trial of CU-20101 for glabellar lines","url":"https://stock-news.laohu8.com/highlight/detail?id=2627886324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627886324?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:12","pubTimestamp":1776046370,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics completed a Phase III trial in China for CU-20101, a botulinum toxin type A injection for moderate to severe glabellar lines.Topline results were already presented, with subject completion in November 2025 and database lock in January 2026.Study met key efficacy goals, showing CU-20101 performed comparably to BOTOX in improving frown lines.Safety profile was favorable, with no treatment-related serious adverse events and no new safety signals.Cutia highlighted a manufacturing approach that avoids animal-derived materials and human serum albumin, supporting product differentiation in aesthetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbJnWwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627100785","title":"Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2627100785","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627100785?lang=en_us&edition=fundamental","pubTime":"2026-04-13 09:52","pubTimestamp":1776045157,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  said it completed a Phase 3 clinical trial in China for its botulinum toxin type A product for treating moderate to severe glabellar lines, according to a Monday Hong Kong bourse filing.The study met primary and secondary endpoints, with efficacy comparable to Botox and a favorable safety profile.The pharmaceutical company said no treatment-related serious adverse events or new safety signals were observed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","BK1161","02487","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627010724","title":"BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101","url":"https://stock-news.laohu8.com/highlight/detail?id=2627010724","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627010724?lang=en_us&edition=fundamental","pubTime":"2026-04-13 09:24","pubTimestamp":1776043447,"startTime":"0","endTime":"0","summary":"BRIEF-Cutia Therapeutics Says Completion Of Phase III Clinical Trial Of Cu-20101April 13 (Reuters) - Cutia Therapeutics 2487.HK:COMPLETION OF PHASE III CLINICAL TRIAL OF CU-20101Further company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40U08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162875392","title":"CUTIA-B Completes Phase III Trial in China for Botulinum Toxin Type A Injection Targeting Glabellar Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=1162875392","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162875392?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:22","pubTimestamp":1776039749,"startTime":"0","endTime":"0","summary":"CUTIA-B (02487) has announced the completion of its Phase III clinical trial in China for CU-20101 (Botulinum Toxin Type A for Injection), aimed at improving moderate to severe glabellar lines. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III","02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627104741","title":"Cutia Therapeutics -  Completion of Phase Iii Clinical Trial of Cu-20101","url":"https://stock-news.laohu8.com/highlight/detail?id=2627104741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627104741?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:08","pubTimestamp":1776038910,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40U08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195016335","title":"Cutia Therapeutics Reports Stable Share Capital in March; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1195016335","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195016335?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:02","pubTimestamp":1775134970,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (CUTIA-B, HKEX: 02487) filed its Monthly Return for the period ended 31 March 2026, indicating no changes in authorised, issued or treasury share balances during the month....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071940","title":"Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071940","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071940?lang=en_us&edition=fundamental","pubTime":"2026-03-26 03:12","pubTimestamp":1774465953,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics (SEHK:2487) opened FY 2025 with first half revenue of C¥66.3 million and a basic EPS loss of C¥0.75, while trailing twelve month revenue sat at C¥336.2 million against a basic EPS loss of C¥1.03. The company reported revenue of C¥95.6 million in the first half of 2024, C¥184.0 million in the second half of 2024, and C¥66.3 million in the first half of 2025, with basic EPS losses of C¥0.66, C¥0.75 and C¥0.75 over those same periods. This sequence highlights that investors...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-sehk2487-margins-stay-deep-in-the-red-cha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2487/cutia-therapeutics-shares/news/cutia-therapeutics-sehk2487-margins-stay-deep-in-the-red-cha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK1161","BK4539","BK4139","02487","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}